Nuwellis, Inc. (NUWE) Pediatric Aquadex Study Supports Label Expansion
阅读少于1分钟
Nuwellis announced publication of a multicenter ULTRA-Peds study in Pediatric Nephrology, evaluating 91 children on Aquadex and supporting its proposed FDA label expansion from ≥20 kg to ≥5 kg.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | Study in 91 pediatric patients | Adds real-world evidence backing expanded pediatric use, a potential market unlock. |
| 2 | 62% weighed <10 kg; 41 <5 kg | Demonstrates feasibility in smallest patients targeted by label expansion. |
| 3 | 87% survived treatment course | Signals acceptable outcomes for high-risk cohort; supports safety/performance. |
| 4 | 86.5% procedures uninterrupted | Indicates device reliability; could aid clinician adoption. |
| 5 | FDA pre-sub completed earlier | Regulatory path active; study may bolster submission for ≥5 kg labeling. |
Context by AI Analyst
This is mid-cycle validation of NUWE’s push to broaden Aquadex into smaller pediatric weights. A formal FDA submission and clearance expanding labeling to ≥5 kg would convert this into a larger commercial catalyst.
Based on the original press release from Nuwellis, Inc. distributed by GlobeNewswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.